Drug Trial Radar · NCT05900401
Delayed Tolerance Through Mixed Chimerism
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 1, 2023
Primary completion
Dec 2031
Study completion Dec 2032
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ossium Health, Inc.; ITB-Med LLC
- First posted
- Jun 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
Conditions
- Kidney Failure
- Kidney Transplant; Complications
- Chimera
Interventions
Bone Marrow TransplantOther
Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
Peripheral Blood Stem Cell CollectionProcedure
PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.
FludarabineDrug
Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)
CyclophosphamideDrug
Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
RituximabDrug
Rituximab on study day -6
SiplizumabDrug
Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of transient mixed chimerismTime frame: 3 months
- Incidence of renal allograft toleranceTime frame: 2 years after immunosuppression withdrawal
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.